BCMA CAR-T细胞调节骨髓瘤长期免疫应答的研究进展
Chinese Journal of Immunology（2023）
Abstract
多发性骨髓瘤是一种异质性的血液肿瘤疾病,在骨髓微环境中,浆细胞恶性增殖导致的肿瘤免疫逃逸和累积的基因组畸变推动了疾病的进展,进展中损伤的免疫功能易使疾病复发.然而,近年来靶向B细胞成熟抗原(BCMA)的嵌合抗原受体T细胞疗法使骨髓瘤症状产生持久且深度的缓解,复发/难治性骨髓瘤的治疗取得了突破性进步.因此,本文综述了BCMA CAR-T治疗复发/难治性骨髓瘤的最新研究进展,为进一步恢复患者抗肿瘤免疫能力及形成长期免疫应答提供参考.
MoreTranslated text
Key words
BCMA,Chimeric antigen receptor-T cells,Relapsed or refractory multiple myeloma,Immune response
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined